NTRK1 Fusion

CI-VAR-00001340Explore in graph →CIViC 4253

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
SCP2::NTRK1 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10897 Of the 4854 Breast Cancer patients analyzed by Memorial Sloan Kettering-IMPACT targeted DNA sequencing and MSK-Fusion targeted RNA-seq, fusions were detected in 27 patients. One of these patients was … (full text at CIViC) PMID 32348852 · Ross et al., 2020 · Open in CIViC	civic
SCP2::NTRK1 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10898 A breast cancer patient harbored the SCP2::NTRK1 fusion. This report demonstrated positive pan-tyrosine receptor kinase (TRK) immunohistochemical staining in a core-needle biopsy taken from the patien… (full text at CIViC) PMID 33002320 · Ruiz-Cordero et al., 2020 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.